Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;44(11):1777-1786.
doi: 10.1007/s00134-018-5227-4. Epub 2018 Oct 21.

Impact of a multifaceted prevention program on ventilator-associated pneumonia including selective oropharyngeal decontamination

Affiliations

Impact of a multifaceted prevention program on ventilator-associated pneumonia including selective oropharyngeal decontamination

C Landelle et al. Intensive Care Med. 2018 Nov.

Abstract

Purpose: We describe the impact of a multifaceted program for decreasing ventilator-associated pneumonia (VAP) after implementing nine preventive measures, including selective oropharyngeal decontamination (SOD).

Methods: We compared VAP rates during an 8-month pre-intervention period, a 12-month intervention period, and an 11-month post-intervention period in a cohort of patients who received mechanical ventilation (MV) for > 48 h. The primary objective was to assess the effect on first VAP occurrence, using a Cox cause-specific proportional hazards model. Secondary objectives included the impact on emergence of antimicrobial resistance, antibiotic consumption, duration of MV, and ICU mortality.

Results: Pre-intervention, intervention and post-intervention VAP rates were 24.0, 11.0 and 3.9 VAP episodes per 1000 ventilation-days, respectively. VAP rates decreased by 56% [hazard ratio (HR) 0.44, 95% CI 0.29-0.65; P < 0.001] in the intervention and by 85% (HR 0.15, 95% CI 0.08-0.27; P < 0.001) in the post-intervention periods. During the intervention period, VAP rates decreased by 42% (HR 0.58, 95% CI 0.38-0.87; P < 0.001) after implementation of eight preventive measures without SOD, and by 70% after adding SOD (HR 0.30, 95% CI 0.13-0.72; P < 0.001) compared to the pre-intervention period. The incidence density of intrinsically resistant bacteria (to colistin or tobramycin) did not increase. We documented a significant reduction of days of therapy per 1000 patient-days of broad-spectrum antibiotic used to treat lower respiratory tract infection (P < 0.028), median duration of MV (from 7.1 to 6.4 days; P < 0.003) and ICU mortality (from 16.2 to 13.5%; P < 0.049) for patients ventilated > 48 h between the pre- and post-intervention periods.

Conclusions: Our preventive program produced a sustained decrease in VAP incidence. SOD provides an additive value.

Keywords: Intensive care unit; Multimodal strategy; Selective oropharyngeal decontamination; Ventilator-associated pneumonia.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

SH reports having received a peer-reviewed research grant funded by Pfizer; he is also a temporary member of the advisory boards of DNA Electronics, Bayer and Novartis. All other authors: none to declare.

Research involving human participants

As a quality improvement project, ethics committee approval was not required.

Figures

Fig. 1
Fig. 1
Compliance over the three periods for the nine ventilator-associated pneumonia (VAP) preventive measures, and for global compliance. Compliance was defined for each assessable preventive measures (represented as a percentage) and global compliance is expressed as median (IQRs) for all ventilator-days assessable; SOD selective oropharyngeal decontamination. a Significant P value between the pre-intervention and intervention periods, b significant P value between the intervention and post-intervention periods, c significant P value between the pre-intervention and post-intervention periods, d significant P value between the three periods
Fig. 2
Fig. 2
Segmented Poisson regression analysis, comparing incidence rates of ventilator-associated pneumonia (VAP) in the pre-intervention, the intervention period without SOD, implementation of SOD and post-intervention period according to months. SOD Selective oropharyngeal decontamination. Circles indicate first VAP incidence rates per 1000 ventilation-days according to months, horizontal lines estimated first VAP incidence rates per 1000 ventilation-days by period, blue line pre-intervention period, red line intervention period without SOD, gray line implementation of SOD period, and green line post-intervention period, vertical orange lines delimitations of time periods, bars VAP number according to months
Fig. 3
Fig. 3
Cumulative cause-specific hazard (a) and daily hazard rates (b) of ventilator-associated pneumonia in the pre-intervention period, the intervention period without SOD, implementation of SOD and the post-intervention period using Cox proportional cause-specific hazard regression. a, b Blue lines represent the pre-intervention period, red lines the intervention period without SOD, gray lines the period after implementation of SOD, green lines the post-intervention period. b Dashed lines empirical daily hazard of VAP, solid lines smoothed hazard function

Comment in

  • Beat around the bush for VA-LRTI.
    Martin-Loeches I, Depuydt P, Niederman MS. Martin-Loeches I, et al. Intensive Care Med. 2018 Nov;44(11):1961-1963. doi: 10.1007/s00134-018-5281-y. Epub 2018 Oct 21. Intensive Care Med. 2018. PMID: 30343316 No abstract available.

References

    1. Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med. 2013;19:216–228. doi: 10.1097/MCP.0b013e32835f27be. - DOI - PubMed
    1. Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13:665–671. doi: 10.1016/S1473-3099(13)70081-1. - DOI - PubMed
    1. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol. 2012;33:250–256. doi: 10.1086/664049. - DOI - PubMed
    1. Hugonnet S, Eggimann P, Borst F, Maricot P, Chevrolet JC, Pittet D. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol. 2004;25:1090–1096. doi: 10.1086/502349. - DOI - PubMed
    1. Klompas M. Ventilator-associated pneumonia: is zero possible? Clin Infect Dis. 2010;51:1123–1126. doi: 10.1086/656738. - DOI - PubMed

Substances